Backed in part by Roche, Den­mark's NMD gets $47M to run or­phan neu­ro­mus­cu­lar dis­ease tri­als

Den­mark start­up NMD Phar­ma has snagged a $47 mil­lion round of fund­ing to push two pro­grams for or­phan neu­ro­mus­cu­lar dis­or­ders in­to proof-of-con­cept stud­ies.

The Se­ries A was backed by new in­vestors Roche Ven­ture Fund and INKEF Cap­i­tal, the lat­ter of which led the round. They were joined by ex­ist­ing in­vestors No­vo Seeds and Lund­beck­fonden Emerge.

NMD is de­vel­op­ing small mol­e­cule in­hibitors of the mus­cle-spe­cif­ic chlo­ride ion chan­nel — the ClC-1 ion chan­nel. The com­pa­ny says ClC-1 in­hi­bi­tion can strength­en neu­ro­mus­cu­lar trans­mis­sion and ul­ti­mate­ly skele­tal mus­cle func­tion in both fast and slow-twitch mus­cle fibers. NMD says the ap­proach showed com­pelling da­ta across sev­er­al or­phan neu­ro­mus­cu­lar dis­eases, in­clud­ing Myas­the­nia Gravis (MG) and Amy­otroph­ic Lat­er­al Scle­ro­sis (ALS).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER